Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

Recruiting

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(6 sites)

Canada

Foothills Medical Centre, Calgary, Alberta

Tom Baker Cancer Centre, Calgary, Alberta

Alberta Children's Hospital, Calgary, Alberta

Cross Cancer Institute, Edmonton, Alberta

Stollery Children's Hospital, Edmonton, Alberta